Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q3 2025 · 10-Q
Revenue$0.00$0.00— vs Q3 2024 Net Income-$4.86M-$4.86MN/M vs Q3 2024 EPS Diluted-$0.49-$0.49N/M vs Q3 2024 Operating Income-$4,879,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$3,119,000N/M ended Mar 31, 2025 · filed May 2, 2025 · 32 d after period end